Company Filing History:
5 out of 1,715 
3 out of 41 Years Active: 2007-2019
Title: **Masanori Goto: Pioneering Innovations in Lectin Research**
Introduction
Masanori Goto is an accomplished inventor based in Tsukuba, Japan, known for his significant contributions to the field of biotechnology and sugar-chain recognition. With a total of five patents to his name, he has paved the way for advancements in the understanding and application of lectins derived from various sources.
Latest Patents
One of Goto's latest patents focuses on a modified lectin derived from Wisteria floribunda. This invention provides a monomeric lectin polypeptide capable of binding specifically to a GalNAc terminal sugar chain. The polypeptide includes various amino acid sequences, allowing for modifications such as deletions, substitutions, or insertions at specific positions. The innovation aims to stably supply high-quality and highly uniform agglutinin (WFA), enhancing the specificity of sugar-chain recognition activity. This development also encompasses cloning techniques to produce recombinant WFA from transformed bacteria, which ultimately has important applications in diagnostics.
Career Highlights
Masanori Goto has had a remarkable career with notable affiliations, including the National Institute of Advanced Industrial Science and Technology and Seikagaku Kogyo Co., Ltd. His work has focused on elucidating the sugar-chain recognition activity and improving the production of natural WFA, emphasizing its relevance in biotechnological applications.
Collaborations
Throughout his career, Goto has collaborated with esteemed colleagues, including Hisashi Narimatsu and Takashi Sato. These collaborations have fostered interdisciplinary research and innovation, contributing to advancements in the field of agglutinin research and its applications.
Conclusion
Masanori Goto continues to be a driving force in the realm of biotechnology, with his inventions and research significantly influencing the understanding of sugar-chain markers. His patents reflect a commitment to improving the specificity and quality of lectins, paving the way for future innovations in diagnostic and therapeutic applications.